Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALKS 2680 in narcolepsy type 2
NL-OMON60841Phase 2Completed
- Sponsor
- Alkermes
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of alixorexton in narcolepsy type 2 (NT2), sponsored by Alkermes. Primary endpoints: Change in mean sleep latency on Maintenance of Wakefulness Test and Change in Epworth Sleepiness Scale. Started Apr 2025; status: completed.
02
Drugs
alixorexton
03
Conditions
narcolepsy type 2 (NT2)
Beyond the preview
Go deeper on NL-OMON60841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60841.